Smman-Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. The total response rate was 32%o (95% confidence interval 24-400o): 13% had a complete remission. Female patients had a significantly higher chance of response than male patients: 46% vs 23%. There was also a difference in complete response rate: 25% vs 9%O. The overall survival was 6 months: 8% of patients had a response of more than 6 months and 2% of more than 2 years. Although response rates vary among the various regimens described in the literature. the complete response rates are quite similar and the long-term disease-free survival of these combinations mav be similar to that of dacarbazine alone.
Smman-Combinations of dacarbazine (DTIC) and other cytotoxic agents or alpha-interferon were given to 136 patients in five different regimens. The total response rate was 32%o (95% confidence interval 24-400o): 13% had a complete remission. Female patients had a significantly higher chance of response than male patients: 46% vs 23%. There was also a difference in complete response rate: 25% vs 9%O. The overall survival was 6 months: 8% of patients had a response of more than 6 months and 2% of more than 2 years. Although response rates vary among the various regimens described in the literature. the complete response rates are quite similar and the long-term disease-free survival of these combinations mav be similar to that of dacarbazine alone. We have over a 7 year period used this drug as part of various combination regimens in 136 consecutive patients with disseminated malignant melanoma (Mulder et al.. 1986 : Buter et al.. 1994 . We report here the short-and long-term outcome of these studies, to provide a measure against which other treatment options can be assessed.
Patients and methods
Five different regimens were used consecutively:
Regimen I Dacarbazine 300mgm~-on 4 consecutive days combined with continuous infusion of bleomycin 30 mg day-', followed on day 5 by vindesine 3 mg m-and actinomycin D 2 mg m-'. Cycles were repeated every 4 weeks (Mulder et al., 1986) . Regimen II The same regimen without actinomycin D (Mulder et al., 1989) . Regimen III DTIC 750mgm--on day 1 and alpha-interferon 9 mU daily for 21 days. given for six cycles in responding patients (Mulder et al.. 1990 ). Regimen IV DTIC 750mgm--on day 1 and alpha-interferon 9 mU given for 28 days, on day 14 5-fluorouracil (5-FU) 1.00 mg m--, six cycles (Mulder et al.. 1992) . Regimen V DTIC 750-1,500 mg m--on day 1 and alphainterferon 9 mU for 21 days, repeated every 3 weeks, combined with daily granulocyte colony-stimulating factor (G-CSF) (Buter et al.. 1994 Patients entered into the five regimens and their characteristics are given in Table I . The complete and partial response rates, the number of patients responding for more than 6 months and the number of patients surviving disease free for more than 2 years are given in Table II . as well as the relation with sex.
The total number of responders is 44 or 32% (95% confidence interval 24-40%); of these 18 or 13% had a complete response. There is no significant difference between the various regimens. The response rate is. however, dependent on gender: the response rate in female patients is 25 out of 54 or 46% and in males is 230% (7 = 7.96. P = 0.004). In complete responders this difference is also significant: 25% vs 9% in males (i' = 3.97. P= 0.04). Responses are also much more common in the lung (39%) and lymph nodes (30%) than in the liver (2%) (Table III) .
In the responding patients 11 responses lasted for more than 6 months (25%). Overall, in all patients treated. the chance of such a prolonged response is 8% (95% confidence (Table  II) .
The toxicity of these regimens has changed dramatically over the treatment period: nausea and vomiting were dose limiting prior to the advent of serotomnn antagonistic drugs, but have been virtually eliminated since. Grade 3 or 4 toxicity occurred in 24 patients, in one mucositis (on actinomycin D), in the others leuco-and thrombopenia; in seven patients toxicity occurred on the DTIC dose escalation regimen (regimen V).
Dicussion
The results of these studies emphasise the problems in the treatment of metastatic melanoma. The chances of prolonged survival are small. In this study only one patient appears to have achieved cure. It has often been questioned whether response has any correlation at all with survival (Balek et al., 1983; Ahmann et al.. 1989) . However, in contrast to those reports, we found no long-term survivors among non-responders. This could be a result of selection of patients with progressive disease in our studies.
Compared with the results of monotherapy with DTIC. combination therapy is associated with considerable toxicity for a marginal benefit. The response rate of DTIC alone is reported to be 20%, with a complete response rate of 5%. Long-term survival is 2% (Hill et al.. 1984) . These results are somewhat. but not much, lower than found in this study. In view of its limited extramedullary toxicity. DTIC can be combined with any drug. The regimens used in this study were inspired by presumed synchronised effects (regimens I and II) or synergy (regimens III and V). Recently, a randomised study found that response duration was increased by some months when interferon was added to DTIC (Bajetta et al., 1994) . In view of the somewhat longer survival with the addition of 5-FU (Table II) , this combination might deserve some further attention.
In general, combination therapy with DTIC. such as the regimens described here or combinations with tamoxifen. cisplatin and nitrosurea, is associated with somewhat higher response rates than monotherapy. Complete response rates hover around 10%. but translation into long-term survival is doubtful. In the occasional reports recording responses of 50% or higher, it is usually the partial response rate rather than the complete response rate that is increased (Pyrh6nen et al., 1992) .
A striking observation in this and some other studies is the much better response rate for women (Presant & Bartolucci, 1982; Luger et al.. 1990 ), a difference that cannot easily be explained.
Given the toxicities of combination chemotherapy or interferon and interleukin 2. a case can be made for mono-DTIC treatment as a first choice outside the setting of a clinical tnal, especially since nausea has almost been abolished. Selection of patients with favourable prognostic cnrtenra. such as female sex and predominant lung metastasis, could result in a fair response rate at the cost of limited toxicity.
Other regimens based not on presently available drug combinations but on new technologies such as specific immunisation or gene transfer seem to be required for an impact on overall survival.
